Arrowhead's Deep Fourth-Quarter Miss Collides With An Accelerated SHTG Timeline And Inflecting REDEMPLO Demand

Arrowhead Pharmaceuticals (NASDAQ: ARWR) badly missed expectations for its fiscal fourth quarter ended September 2026. The company lost $3.04 per share, compared with the consensus estimate of -$1.59 and the Earnings Whisper number of -$1.76, an earnings shortfall of 72.7%. Revenue of $37.79 million came in 43.0% below the $66.26 million consensus and fell 85.3% from a year earlier, while earnings fell 1588.9% year over year. On the numbers alone, this was an unambiguous miss. That is the central tension: the quarter delivered almost nothing financially, yet it materially de-risked the asset that drives the investment case. Severe hypertriglyceridemia (sHTG) moved from pivotal data to a filed sNDA under an expedited FDA pathway.

The quality of the reported results deserves scrutiny. For the full fiscal year, revenue fell to $450.8 million from $829.4 million, a comparison distorted by one-time Sarepta revenue recognition in fiscal 2025. Total operating expenses rose to $1.16 billion from $731 million. That figure includes a $215 million charge for an acquired Priority Review Voucher. Even excluding the voucher, operating expenses of roughly $943 million were up sharply, as R&D climbed to $739 million and SG&A rose to $202 million to support the commercial build. The net loss attributable to Arrowhead was $724 million, or $5.11 per share, compared with essentially breakeven a year ago. The balance sheet also shifted. Total cash resources ended at about $1.19 billion, up year over year after $683 million of convertible notes were added, but down from roughly $1.6 billion at June 30. Stockholders' equity shrank to $50 million from $466 million.

Beneath that, the commercial picture improved meaningfully, even though the dollars remain small. New-to-brand REDEMPLO prescriptions grew 63% quarter over quarter. Cumulative scripts reached 950 at fiscal year-end and exceeded 1,250 by early November. The weekly run rate rose to roughly 50-60, up from the 20-30 per week cited a quarter earlier. Unique prescribers climbed from more than 400 to over 640 at year-end and above 860 since then, and U.S. formulary coverage now reaches 160 million lives. Even so, fiscal 2026 net product revenue was only about $6.6 million. Management openly described prescription-to-paid-shipment conversion as a choke point, declined to offer revenue guidance, and steered investors toward leading indicators instead. Bears have legitimate ammunition here: script momentum is not yet translating into revenue at a pace that offsets a near-billion-dollar expense base.

The bigger development is timing. In the second quarter, the company pointed to standard review and a second-half 2027 sHTG approval. It then bought a priority review voucher. It has now secured entry into the FDA's STAR pilot program, filed the sNDA on November 2, and is targeting a U.S. sHTG launch in the second quarter of 2027. Because STAR qualifies the application for a six-month Priority Review, the voucher is no longer needed. The call cited recent market comparables of $180-220 million for such vouchers, a potential source of non-dilutive cash. The SHASTA-3 and SHASTA-4 data support the filing:

• median triglyceride reductions of 79% and 81%;
• a 78% reduction in acute pancreatitis events;
• a 91% reduction in patients with prior pancreatitis.

Platform news added optionality. ARO-MAPT reduced cerebrospinal fluid tau by a mean of 73% with subcutaneous dosing, well above the 50-60% bar management set last quarter. ARO-DIMER-PA validated dual-gene silencing. The Sixth Street refinancing cut the borrowing rate from 15% to SOFR plus 5.5%, removed cash sweeps, and extended maturity to 2031. Management's tone was notably more confident.

The risks are real, however. Competitor Ionis guided to a softer-than-expected early sHTG launch, which raises questions about how quickly that market develops. The detailed SHASTA data showed worsening glycemic control in 14.3% of treated patients versus 8.7% on placebo. ARO-DIMER-PA produced immune-related adverse events, and dose selection remains open. Management itself expects broad sHTG penetration to take years and to depend on payer policy.

The market had already priced in considerable skepticism. As of November 11, shares were $49.36, down 43.6% from the $87.49 open after the August report. They sat 30.7% below the 200-day moving average and just 6.3% above the inter-earnings low of $46.45 set on November 9, far from the $90.97 high in mid-August. Earnings Whispers investor sentiment nonetheless improved modestly, from 0.14 to 0.23, staying positive and firming into the report. The trend readings are mixed: momentum is positive, while price and AVWAP trends remain negative.

The bottom line is that Arrowhead's fourth-quarter miss was steep, and the financials offer little comfort: revenue is negligible, losses are large, and cash fell by roughly $400 million in a single quarter. The call, however, preserved a credible and now faster sHTG story, backed by accelerating prescription demand, a saleable voucher, and cheaper debt. With the stock entering the report near its lows, the setup now hinges on two things: whether the prescription funnel converts to paid revenue, and whether the STAR review delivers the promised second-quarter 2027 launch.

Read our earnings preview for Arrowhead Pharmaceuticals, Inc.: https://www.earningswhispers.com/article/ARWR/22909

This earnings review was originally published on Earnings Whispers.

This article is for informational purposes only and is not investment advice. Earnings Whispers and its staff may hold positions in the securities mentioned. It is AI-assisted, based on proprietary Earnings Whispers data and company reports, and edited by Earnings Whispers staff.